No annual revenue total was found in DRUGS MADE IN AMERICA ACQUISITION CORP.'s SEC filings.
Drugs Made In America Acquisition Corp. (DMAA) files with the SEC under industry code 6770, Blank Checks.
Revenue
—
Net income (TTM)
$6.09M
Operating cash flow (TTM)
$-517,145
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
33.72M
+0.6% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Blank Checks (SIC 6770)
- Listed as
- DMAA (Nasdaq), DMAAR (Nasdaq), DMAAU (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- New York, NY
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2028614
Other Blank Checks companies
- Drugs Made In America Acquisition II Corp. DMII
- EQV Ventures Acquisition Corp. II EVAC
- Bain Capital GSS Investment Corp. BCSS
- Cantor Equity Partners IV, Inc. CEPF
- Churchill Capital Corp XII CXII
- American Exceptionalism Acquisition Corp. A AEXA
- New America Acquisition I Corp. NWAX
- Ares Acquisition Corp III AAC
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
|---|---|
| Operating income | -$2.8M |
| Net income | $5.9M |
| Operating cash flow | -$539,187 |
| Total assets | $239.9M |
| Total liabilities | $7.3M |
| Stockholders' equity | -$7.3M |
| Cash and investments | $6,137 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Other events
|
Oct 21, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Material agreement
|
Sep 14, 2026 | Sep 8, 2026 |
| 10-Q | Quarterly report | Aug 14, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement
|
Jul 20, 2026 | Jul 14, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement
|
May 5, 2026 | Apr 29, 2026 |
All 80 Drugs Made In America Acquisition Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.